.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,598,129

« Back to Dashboard

Details for Patent: 8,598,129

Title:Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Abstract: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica milliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Inventor(s): Manetta; Vincent (Bordentown, NJ), Watkins; Gary R. (Piscataway, NJ)
Assignee: Galderma S.A. (Cham, CH)
Filing Date:Mar 27, 2013
Application Number:13/851,816
Claims:1. A method for the treatment of common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetostearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid, palmitostearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; ivermectin; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water; said emulsion being chemically stable over a period of time of 8 weeks.

2. The method as defined by claim 1, wherein the topical pharmaceutical emulsion comprises: 3 to 50% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetostearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid, palmitostearic acid and self-emulsifiable wax; up to 15% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 0.1 to 20% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water; said emulsion being chemically stable over a period of time of 8 weeks.

3. The method as defined by claim 1, wherein the topical pharmaceutical emulsion comprises: 6 to 20% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetostearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid, palmitostearic acid and self-emulsifiable wax; up to 15% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 0.1 to 20% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water; said emulsion being chemically stable over a period of time of 8 weeks.

4. The method as defined by claim 1, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants.

5. The method as defined by claim 1, and topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide.

6. A method for the treatment of common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetostearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of one or more gelling agents selected from the group consisting of carbomers; and water; said emulsion being chemically stable over a period of time of 8 weeks.

7. A method for the treatment of common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetostearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water; said emulsion being chemically stable over a period of time of 8 weeks.

8. The method as defined by claim 7, wherein the topical pharmaceutical emulsion comprises: 6 to 20% by weight of an oily phase comprising dimethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, stearyl alcohol, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks.

9. The method as defined by claim 8, wherein the topical pharmaceutical emulsion comprises: 6 to 20% by weight of an oily phase comprising dimethicone and isopropyl palmitate, said oily phase further comprising fatty substances selected from the group consisting of palmitostearic acid, self-emulsifiable wax, cetyl alcohol and stearyl alcohol; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, Steareth-20 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, glyceryl triacetate, oleyl alcohol and phenoxyethanol; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks.

10. The method as defined by claim 9, wherein the topical pharmaceutical emulsion comprises: 6 to 20% by weight of an oily phase comprising dimethicone, isopropyl palmitate, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of glyceryl/PEG stearate, sorbitan monostearate and Steareth-20 as surfactant-emulsifiers; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of the solvents and/or propenetrating agents propylene glycol, glyceryl triacetate and phenoxyethanol; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks.

11. The method as defined by claim 1, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants.

12. The method as defined by claim 1, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide.

13. The method as defined by claim 8, said topical pharmaceutical emulsion comprising: TABLE-US-00010 Ivermectin 1.00 Glycerol 4.0 Aluminum magnesium silicate 1.0 Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl palmitate 4.0 Glyceryl/PEG 100 stearate 3.0 Self-emulsifiable wax 2.0 Palmitostearic acid 2.5 Steareth-20 3.0 Sorbitan stearate 2.0 Dimethicone 20 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 4.0 Glyceryl triacetate 1.0 Phenoxyethanol 0.5 10% sodium hydroxide qs pH Water qs 100

as % by weight relative to the total weight of the composition.

14. The method as defined by claim 9, said topical pharmaceutical emulsion comprising: TABLE-US-00011 Ivermectin 1.00 Glycerol 4.0 Aluminum magnesium silicate 1.0 Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl palmitate 4.0 Glyceryl/PEG 100 stearate 3.0 Self-emulsifiable wax 2.0 Palmitostearic acid 3.0 Steareth-20 3.0 Sorbitan stearate 2.0 Dimethicone 20 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 4.0 Glyceryl triacetate 1.0 Phenoxyethanol 0.5 10% sodium hydroxide qs pH Water qs 100

as % by weight relative to the total weight of the composition.

15. A method for the treatment of common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; ivermectin; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol; phenoxyethanol and glyceryl triacetate; acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a period of time of 12 weeks.

16. The method as defined by claim 15, wherein said at least one surfactant-emulsifier is present in an amount of up to 15% by weight.

17. The method as defined by claim 15, wherein said ivermectin is present in an amount of 0.1 to 5% by weight.

18. The method as defined by claim 15, wherein said mixture of solvents and/or propenetrating agents is present in an amount of 0.1 to 20% by weight.

19. The method as defined by claim 15, wherein said one or more gelling agents is/are present in an amount of 0.01 to 5% by weight.

20. A method for the treatment of common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 3 to 50% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; up to 15% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 0.1 to 20% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a period of time of 12 weeks.

21. The method as defined by claim 15, wherein: said oily phase comprises dimethicone and isopropyl palmitate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol and stearyl alcohol; said at least one surfactant-emulsifier is selected from the group consisting of sorbitan monostearate and Ceteareth-20; and said mixture of solvents and/or propenetrating agents is selected from the group consisting of propylene glycol, oleyl alcohol and phenoxyethanol.

22. The method as defined by claim 15, wherein: said oily phase comprises dimethicone, isopropyl palmitate, cetyl alcohol and stearyl alcohol; said at least one surfactant-emulsifier is sorbitan monostearate and Ceteareth-20; and said mixture of solvents and/or propenetrating agents is a mixture of propylene glycol, oleyl alcohol and phenoxyethanol.

23. The method as defined by claim 15, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants.

24. The method as defined by claim 15, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide.

25. A method for the treatment of common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; up to 15% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 0.1 to 20% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a period of time of 12 weeks.

26. The method as defined by claim 25, wherein the topical pharmaceutical emulsion comprises: 6 to 20% by weight of an oily phase comprising dimethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, stearyl alcohol, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a period of time of 12 weeks.

27. The method as defined by claim 25, wherein the topical pharmaceutical emulsion comprises: 6 to 20% by weight of an oily phase comprising dimethicone and isopropyl palmitate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol and stearyl alcohol; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of sorbitan monostearate and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol and phenoxyethanol; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a period of time of 12 weeks.

28. The method as defined by claim 25, wherein the topical pharmaceutical emulsion comprises: 6 to 20% by weight of an oily phase comprising dimethicone, isopropyl palmitate, cetyl alcohol and stearyl alcohol; 2 to 12% by weight of sorbitan monostearate and Ceteareth-20 as surfactant emulsifiers; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of the solvents and/or propenetrating agents propylene glycol, oleyl alcohol and phenoxyethanol; 0.01 to 5% by weight of acrylate C10-C30 alkyl acrylate crosspolymer gelling agent; and water; said emulsion being chemically stable over a period of time of 12 weeks.

29. The method as defined by claim 26, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants.

30. The method as defined by claim 26, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide.

31. The method as defined by claim 27, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants.

32. The method as defined by claim 27, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide.

33. The method as defined by claim 28, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants.

34. The method as defined by claim 28, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide.

35. The method as defined by claim 28, further comprising glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide.

36. The method as defined by claim 26, said topical pharmaceutical emulsion comprising: TABLE-US-00012 Ivermectin 1.00 Glycerol 4.0 Acrylate C10-30 alkyl acrylate 0.15 crosspolymer Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl myristate 4.0 Cetyl alcohol 3.0 Stearyl alcohol 2.0 Self-emulsifiable wax 0.8 Palmitostearic acid 0.5 Steareth-20 2.0 Sorbitan palmitate 1.0 Dimethicone 20 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 4.0 Glyceryl triacetate 1.0 Phenoxyethanol 0.5 10% sodium hydroxide qs pH Water qs 100

as % by weight relative to the total weight of the composition.

37. A method for the treatment of common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, the topical pharmaceutical emulsion which comprises: TABLE-US-00013 Ivermectin 1.00 Glycerol 4.0 Acrylate C10-30 alkyl acrylate 0.2 crosspolymer Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl palmitate 4.0 Cetyl alcohol 3.5 Stearyl alcohol 2.5 Oleyl alcohol 2.0 Ceteareth-20 3.0 Sorbitan monostearate 2.0 Dimethicone 200 20 cs 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 2.0 Phenoxyethanol 1.0 10% sodium hydroxide qs pH Water qs 100

as % by weight relative to the total weight of the emulsion.

38. A method for the treatment of common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, the topical pharmaceutical emulsion which comprises: TABLE-US-00014 Ivermectin 1.4 Glycerol 4.0 Acrylate C10-30 alkyl acrylate 0.2 crosspolymer Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl palmitate 4.0 Cetyl alcohol 3.5 Stearyl alcohol 2.5 Oleyl alcohol 2.0 Ceteareth-20 3.0 Sorbitan monostearate 2.0 Dimethicone 200 20 cs 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 2.0 Phenoxyethanol 1.0 10% sodium hydroxide qs pH Water qs 100

as % by weight relative to the total weight of the emulsion.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc